Heparin Market Size to Reach USD 7,594.4 Million in 2028 By Reports And Data

The global heparin market size is expected to reach USD 7,594.4 Million in 2028 and register a CAGR of 1.4% over the forecast period, according to the latest report by Reports and Data. Steady global heparin market revenue growth can be attributed to rising prevalence of chronic diseases and increasing number of patients with kidney disease. Patients suffering from chronic kidney disease are at high risk of hemorrhage and thrombotic events. Chronic kidney disease at early stages is mostly related with prothrombotic tendency, while in advanced stages, platelets start to dysfunction owing to exposure to uremic toxin, resulting in increased tendency of bleeding. Thus, patients suffering from chronic kidney disease generally require anticoagulants like heparin to prevent or cure thromboembolic diseases. At present, low-molecular weight heparins are widely used due to fewer occurrences of bleeding and thrombocytopenia induced by heparin.

Rise in number of surgical procedures in hospitals and growing use of anticoagulating agents are other factors supporting market growth. Heparin finds application in preventing clotting of blood during bypass surgery, open-heart surgery, and kidney dialysis. In low doses, use of heparin prevents blood clot formation in patients during a surgical procedure.

Top Players in the Global Heparin Market: Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sanofi SA, B. Braun Melsungen AG, GlaxoSmithKline PLC, LEO Pharma A/S, Aspen Holdings, Fresenius SE & Co. KGaA, and Viatris Inc.

Get a sample copy of the global Heparin market report @ https://www.reportsanddata.com/sample-enquiry-form/4120

Increasing development of on-demand, digitally enabled, and seamlessly connected clinician-patient interactions to manage patient base is expected to drive pharma and healthcare market in the coming years. After the COVID-19 outbreak there has been a number of foundational shifts in the healthcare system. Some of the examples include increasing consumer involvement in health care decision-making, the rapid adoption of virtual health & other digital innovations, increasing focus on utilization of interoperable data & data analytics, and increased public-private collaborations in therapeutics and vaccine development. The increased public-private collaborations for vaccine development has arisen due to high pressure of regional governments. Health care providers, and other stakeholders have invested heavily to quickly pivot, adapt, and innovate therapeutics.

For the purpose of this report, Reports and Data has segmented the heparin market based on product type, route of administration, application, end-use, and region:

Product Type Outlook (Revenue, USD Million; 2018-2028)

Unfractionated Heparin
Low Molecular Weight Heparin
Ultra-low Molecular Weight Heparin

Route of Administration (Revenue, USD Million; 2018-2028)

Subcutaneous
Intravenous

Application Outlook (Revenue, USD Million; 2018-2028)

Coronary Artery Disease
Venous Thromboembolism
Atrial Fibrillation
Renal Impairment
Others

End-Use Outlook (Revenue, USD Million; 2018-2028)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Buy now@ https://www.reportsanddata.com/checkout-form/4120

Application Outlook (Revenue, USD Billion; 2018 – 2028)

Radiology/General Imaging
Obstetrics/Gynaecology
Cardiology
Urology
Vascular
Orthopaedic and Musculoskeletal
Pain Management
Others

End User Outlook (Revenue, USD Billion; 2018 – 2028)

Hospitals
Surgical Centres
Diagnostic Centres
Maternity Centres
Ambulatory Care Centres
Research and Academia
Other

Key Regional Markets Studied in the Report:

North America (U.S., Canada)
Europe (U.K., Italy, Germany, France, Rest of EU)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
The Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/4120

Some Key Highlights From the Report:

By product type, low-molecular weight heparin segment accounted for largest revenue share in 2020. Low-molecular weight heparin offers various benefits over unfractionated heparin, such as longer half-life, better bioavailability, simplified dosing, lower risk of heparin-induced thrombocytopenia, predictable anticoagulant response, and reduced risk of osteoporosis.

By application, venous thromboembolism segment accounted for second-largest revenue share in 2020. Low-molecular weight heparin is garnering increasing demand to treat venous thromboembolism as subcutaneous injection can be started or finished in the outpatient setting without any chance of increasing danger of bleeding complications or recurrent thromboembolism.

Heparin market in North America accounted for largest revenue share in 2020, which can be attributed to growing healthcare burden of chronic diseases and increase in number of drug approvals. In addition, presence of leading market players in the region are causative of robust market revenue growth.

In July 2019, Valeo Pharma Inc. entered into a licensing contract with an International pharmaceutical company for registration, distribution, and marketing of a biosimilar for low molecular weight heparin in Canada...Continued

Highlights of the TOC:

Chapter 1. Market Synopsis

1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique

Chapter 2. Executive Summary

2.1. Summary Snapshot, 2020-2028

Chapter 3. Indicative Metrics

Chapter 4. Heparin Market Segmentation & Impact Analysis

4.1. Heparin Market Material Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers’ analysis
4.2.2.1. Rising incidence of chronic diseases

Continue…

To know more about the report @ https://www.reportsanddata.com/report-detail/heparin-market

Thank you for reading our report. Please get in touch with our team to get a customized version of this report.

Browse Related Reports-

Blood Screening Market Growth@ https://www.reportsanddata.com/report-detail/blood-screening-market

Hospital Acquired Infections (HAI) Diagnostics Market Forecast @ https://www.reportsanddata.com/report-detail/hospital-acquired-infections-hai-diagnostics-market

Respiratory Syncytial Virus Diagnostic Market Demand @ https://www.reportsanddata.com/report-detail/respiratory-syncytial-virus-diagnostic-market

HLA Typing for Transplant Market Growth@ https://www.reportsanddata.com/report-detail/hla-typing-for-transplant-market

Contact Us:

John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Read Our Innovative Blogs @ https://www.reportsanddata.com/blogs
Visit our blog for more industry updates @ https://www.reportsanddata.com/blogs

About Reports and Data:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

This release was published on openPR.